ANI PR Wire
05 May 2023, 15:30 GMT+10
Geneva [Switzerland], May 5 (ANI/PRNewswire): The first US patient has been enrolled in the SELUTION4SFA Sirolimus DEB study by Dr Arthur Lee at the Cardiac & Vascular Institute in Florida. This study evaluates SELUTION SLR in the treatment of occlusive disease of the superficial femoral artery (SFA) and proximal popliteal artery (PPA) and has been designed to support FDA approval. It follows Investigational Device Exemption (IDE) approval in the US in August 2022. SELUTION SLR is the first and only limus release drug-eluting balloon (DEB) to receive FDA IDE approval for SFA and PPA indications.
SELUTION4SFA is being conducted in over 30 centers in the US plus an additional 10 centers worldwide. The study will enroll 300 patients, with the aim of demonstrating the superiority of SELUTION SLR over balloon angioplasty (POBA). The primary efficacy endpoint is primary patency of the target lesion at 12 months and the primary safety endpoint is freedom from death at 30 days. Enrollment into the study will be complete by the end of 2023.
"We are excited to introduce the first Sirolimus DEB to US patients, and look forward to a rapid enrollment of this important study," commented Dr Jay Mathews, Co-Principal Investigator, Manatee Memorial Hospital, Bradenton, Florida. "We hope to learn how this technology can potentially benefit patients with complex peripheral arterial disease."
"We are pleased to be enrolling our third IDE study in US patients, and look forward to the results of these three studies as well as future IDE studies to come," added Jeffrey B. Jump, Chairman and CEO of MedAlliance.
SELUTION SLR was awarded CE Mark Approval for the treatment of coronary artery disease in May 2020. MedAlliance was the first drug-eluting balloon company to receive FDA Breakthrough Designation status. Currently, three IDE clinical studies are evaluating SELUTION SLR in the US: in CLTI patients with BTK disease; SFA/PPA; and coronary ISR. In addition, MedAlliance received IDE approval for de novo coronary artery lesions in January 2023. This complements the substantial experience that the company has gained with the SELUTION DeNovo and SUCCESS trials in Europe.
MedAlliance's unique DEB technology involves MicroReservoirs which contain a combination of biodegradable polymer intermixed with the anti-restenotic drug sirolimus, applied as a coating on the surface of an angioplasty balloon. These MicroReservoirs provide controlled and sustained release of the drug for up to 90 days. MedAlliance's proprietary CAT (Cell Adherent Technology) enables the MicroReservoirs to be coated onto balloons and efficiently transferred to adhere to the vessel lumen when delivered via expansion of the balloon.
SELUTION SLR is commercially available in Europe, Asia, the Middle East, and the Americas (outside USA) and most other countries where the CE Mark is recognized. Over 10,000 units have been used for patient treatments in routine clinical practice or as part of coronary clinical trials. Please contact us if your centre is interested in participating in this study.
MedAlliance is medical technology company which announced a staged acquisition by Cordis in October 2022. It is headquartered in Nyon, Switzerland. MedAlliance specializes in the development of ground-breaking technology and commercialization of advanced drug device combination products for the treatment of coronary and peripheral artery disease. For further information, visit: www.medalliance.com
Media Contact:
Richard Kenyon
rkenyon@medalliance.com
+44 7831 569940
This story is provided by PRNewswire. ANI will not be responsible in any way for the content of this article. (ANI/PRNewswire)
Get a daily dose of Cambodian Times news through our daily email, its complimentary and keeps you fully up to date with world and business news as well.
Publish news of your business, community or sports group, personnel appointments, major event and more by submitting a news release to Cambodian Times.
More InformationIsrael has acknowledged and thanked the United States and President Joe Biden for standing firmly by Israel's side at the ...
NEW YORK: This week, New York City officials said that one person was killed and six others were injured when ...
NEW YORK, New York - The United Kingdom refrained from supporting demands for a ceasefire in the two-months long Israel-Gaza ...
NEW YORK, New York - The U.S. was alone on Friday in a 13-1 vote for a ceasefire in the ...
WASHINGTON D.C.: The Associated Press (AP) reported that Manuel Rocha, a former American diplomat who served as U.S. ambassador to ...
MADISON, Wisconsin: On November 30, Hridindu Sankar Roychowdhury from Wisconsin pleaded guilty to firebombing a conservative anti-abortion group's office on ...
(Photo credit: Ron Chenoy-USA TODAY Sports) Back on track with an improved offense, the Winnipeg Jets will move on to ...
(Photo credit: Brad Penner-USA TODAY Sports) LSU quarterback Jayden Daniels won the Heisman Trophy as the nation's most outstanding college ...
(Photo credit: Joe Nicholson-USA TODAY Sports) Grambling State coach Donte' Jackson knows the drill all too well. After returning home ...
(Photo credit: Dale Zanine-USA TODAY Sports) The NBA fined Atlanta Hawks guard Trae Young $25,000 for confronting a game official ...
(Photo credit: Rick Scuteri-USA TODAY Sports) The Chicago White Sox acquired catcher Max Stassi from the Braves on Saturday, 24 ...
(Photo credit: Danny Wild-USA TODAY Sports) Bryson Daily passed for a touchdown, Kalib Fortner scored a key defensive TD and ...